Serum concentrations of leptin, adiponectin and resistin, and their relationship with cardiovascular disease in patients with end-stage renal disease

被引:110
作者
Díez, JJ
Iglesias, P
Fernández-Reyes, MJ
Aguilera, A
Bajo, MA
Alvarez-Fidalgo, P
Codoceo, R
Selgas, R
机构
[1] Hosp Ramon & Cajal, Dept Endocrinol, E-28034 Madrid, Spain
[2] Hosp La Paz, Dept Biochem, Madrid, Spain
[3] Hosp La Paz, Dept Nephrol, Madrid, Spain
[4] Hosp La Princesa, Dept Nephrol, Madrid, Spain
[5] Gen Hosp, Dept Endocrinol, Segovia, Spain
[6] Gen Hosp, Dept Nephrol, Segovia, Spain
关键词
D O I
10.1111/j.1365-2265.2005.02207.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background High levels of some adipocytokines have been reported in patients with chronic renal failure, but little information is available on adipocytokine concentrations in uraemic patients under different modalities of therapy. Our aims were (1) to quantify the serum concentrations of leptin, adiponectin and resistin in uraemic patients on peritoneal dialysis (PD) and haemodialysis (HD), in comparison with patients on conservative management, and (2) to study the relationships between adipocytokine levels and previous atherosclerotic vascular disease. Patients and Measurements We studied 82 dialysis patients treated by PD (n = 44, 23 males and 21 females, mean age 54.4 +/- 1.8 years) or HD (n = 38, 22 males and 16 females, age 60.8 +/- 1.6 years). A group of 19 uraemic patients on conservative management served as the control. Serum concentrations of leptin, adiponectin and resistin were measured in all subjects. Information on vascular disease (cerebral vascular, peripheral vascular and heart disease) was obtained from a detailed medical history. Results PD patients showed significantly higher serum leptin concentrations [median (interquartile range), 28.7 (13.0-71.9) mug/l] than those found in patients on HD [9.7 (4.7-31.9) mug/l, P < 0.01] or in conservative management [5.9 (4.3-38.6) mug/l, P < 0.05]. Adiponectin concentrations were similar in the three groups of patients (mean +/- SEM, 48.0 +/- 4.5 mg/l in PD, 57.7 +/- 4.4 mg/l in HD, and 44.4 +/- 7.0 mg/l in controls, NS). Patients treated by both PD and HD exhibited resistin concentrations significantly higher than those found in controls (26.3 +/- 0.99 and 27.5 +/- 1.4 mug/l, respectively, vs. 17.3 +/- 1.0 mug/l, P < 0.001). Leptin concentrations were positively correlated with body mass index (BMI) (r = 0.287, P < 0.01) and adiponectin levels were negatively related to BMI (r = -0.416, P < 0.001) and the homeostatic model assessment (HOMA-R) index (r =-0.216, P < 0.05). Leptin, adiponectin and resistin levels in patients with previous vascular events were similar to those found in patients without these complications. Logistic regression analysis did not demonstrate any relationship between serum adipocytokine concentrations and the presence of vascular disease of any type. A significant relationship between resistin and heart disease [odds ratio (OR) 1.80 (1.03-3.15), P = 0.039] was found when analysing subgroups of patients. Conclusions These data suggest that leptin levels are higher in PD patients, and resistin levels are higher in PD and HD patients in relation to patients on conservative management, whereas adiponectin concentrations are similar in the three groups. These results do not support the presence of a clinically relevant relationship between adipocytokines and previous episodes of vascular disease in the whole population or in patients classified in subgroups, with the only exception of a relationship between resistin levels and heart disease.
引用
收藏
页码:242 / 249
页数:8
相关论文
共 31 条
[1]   Eating behavior disorders in uremia:: A question of balance in appetite regulation [J].
Aguilera, A ;
Codoceo, R ;
Bajo, MA ;
Iglesias, P ;
Diéz, JJ ;
Barril, G ;
Cigarrán, S ;
Alvarez, V ;
Celadilla, O ;
Fernández-Perpén, A ;
Montero, A ;
Selgas, R .
SEMINARS IN DIALYSIS, 2004, 17 (01) :44-52
[2]   The associations between plasma adiponectin, ghrelin levels and cardiovascular risk factors [J].
Choi, KM ;
Lee, J ;
Lee, KW ;
Seo, JA ;
Oh, JH ;
Kim, SG ;
Kim, NH ;
Choi, DS ;
Baik, SH .
EUROPEAN JOURNAL OF ENDOCRINOLOGY, 2004, 150 (05) :715-718
[3]   The role of the novel adipocyte-derived hormone adiponectin in human disease [J].
Díez, JJ ;
Iglesias, P .
EUROPEAN JOURNAL OF ENDOCRINOLOGY, 2003, 148 (03) :293-300
[4]   C-reactive protein and cardiovascular disease in peritoneal dialysis patients [J].
Ducloux, D ;
Bresson-Vautrin, C ;
Kribs, M ;
Abdelfatah, A ;
Chalopin, JM .
KIDNEY INTERNATIONAL, 2002, 62 (04) :1417-1422
[5]   Association between adiponectin and mediators of inflammation in obese women [J].
Engeli, S ;
Feldpausch, M ;
Gorzelniak, K ;
Hartwig, F ;
Heintze, U ;
Janke, J ;
Möhlig, M ;
Pfeiffer, AFH ;
Luft, FC ;
Sharma, AM .
DIABETES, 2003, 52 (04) :942-947
[6]   Clinical epidemiology of cardiovascular disease in chronic renal disease [J].
Foley, RN ;
Parfrey, PS ;
Sarnak, MJ .
AMERICAN JOURNAL OF KIDNEY DISEASES, 1998, 32 (05) :S112-S119
[7]   Hyperleptinemia in uremic patients undergoing conservative management, peritoneal dialysis, and hemodialysis:: A comparative analysis [J].
Fontán, MP ;
Rodríguez-Carmona, A ;
Cordido, F ;
García-Buela, J .
AMERICAN JOURNAL OF KIDNEY DISEASES, 1999, 34 (05) :824-831
[8]   Circulating resistin levels in essential hypertension [J].
Furuhashi, Masato ;
Ura, Nobuyuki ;
Higashiura, Katsuhiro ;
Murakami, Hideyuki ;
Shimamoto, Kazuaki .
CLINICAL ENDOCRINOLOGY, 2003, 59 (04) :507-510
[9]  
Heimburger O, 1997, J AM SOC NEPHROL, V8, P1423
[10]   Adiponectin in peritoneal dialysis patients: A comparison with hemodialysis patients and subjects with normal renal function [J].
Huang, JW ;
Yen, CJ ;
Chiang, HW ;
Hung, KY ;
Tsai, TJ ;
Wu, KD .
AMERICAN JOURNAL OF KIDNEY DISEASES, 2004, 43 (06) :1047-1055